Disposition of patients
dyspepsia
ADVERSE EVENTS
A total of 180 patients were recruited by 17 participating centres and were randomized (90 to domperidone and 90 to placebo). Four patients in the placebo group and three patients in the domperidone group were excluded, two of them due to negative RT-qPCR test for SARS-CoV-2 at baseline and the remaining did not take the study treatment. At follow-up, eight patients (four in each study group) withdrew from the study because of patient’s own decision in two, four lost to follow-up and two due to adverse events (abdominal discomfort and dyspepsia). The final evaluable ITT population included 173 patients, 87 in the domperidone group and 86 in the placebo group. The flow chart of the study population is shown in Flow chart of the study population. Analysis was based on the ITT dataset.